Art. -Nr.: HY-N7141

Copy Link Print Information

Spiramycin I

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Spiramycin I is a macrolide antibiotic and antiparasitic.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 91.52%
CAS. Nr.: 24916-50-5
Formel: C₄₃H₇₄N₂O₁₄
Molecular Weight:843.05

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Spiramycin I Chemical Structure

CAS. Nr.: 24916-50-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Spiramycin I is a macrolide antibiotic and antiparasitic^[1].

IC₅₀ & Target

Macrolide

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	189 μM Compound: Spiramycin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 34894691]
HeLa	IC₅₀	34.41 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HepG2	IC₅₀	30.51 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
KB	IC₅₀	31.26 μM Compound: 1	Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
MCF7	IC₅₀	33.11 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
NHDF	IC₅₀	31.1 μM Compound: 1	Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]

In Vitro

Spiramycin I binds to the 50S subunit of the ribosome, blocks the channel for peptide chain synthesis, thereby exhibiting inhibitory activity against Gram-positive bacteria. Spiramycin I inhibits B. subtilis, M. luteus, S. aureus, S. epidermidis, and S. pneumoniae with MICs of 0.5-8 μg/mL^[2].
Spiramycin I (0.1-20 μM, 72 h) exhibits cytotoxicity in cancer cells HeLa, KB, MCF-7, HepG2 and U87 with IC₅₀ of 34.41, 31.26, 33.11, 30.51 and 31.10 μM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[2]

Cell Line:

HeLa, KB, MCF-7, HepG2 and U87
Concentration:

0.1-20 μM
Incubation Time:

72 h
Result:

Inhibited the cell proliferation.

Chemical Information

CAS. Nr. 24916-50-5
Appearance Solid
Molecular Weight 843.05
Formel C₄₃H₇₄N₂O₁₄
Color Off-white to light yellow
SMILES

O=CC[C@@H](C[C@H]([C@H](/C=C/C=C/C[C@H](OC(C[C@H]([C@@H]1OC)O)=O)C)O[C@@H]2O[C@@H]([C@H](CC2)N(C)C)C)C)[C@@H]1O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C)O[C@H]4C[C@@](O)([C@H]([C@@H](O4)C)O)C)N(C)C)O
Structure Classification
- Antibiotics
- Macrolide Antibiotics
Initial Source
- Microorganisms
Streptomyces ambofaciens
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All

Sort by:

Journal Impact Factor

Int J Biol Macromol

Molecular basis of BACE1 modulation revealed by machine learning, molecular simulations, and experimental validation. [Abstract]

2026 May 6:152409. PMID: 42103119
Int J Biol Macromol

Structural and dynamic characterization of papain-like protease ligand recognition using integrated computational and biochemical approaches. [Abstract]

2026 Mar 18:355:151493. PMID: 41861871
Anticancer Res

Gossypol Inhibits GLI3-dependent SHH Signaling to Selectively Target SPOP-deficient Breast Cancer Cells. [Abstract]

2026 May;46(5):2317-2327. PMID: 42049345

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (118.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1862 mL

5.9308 mL

11.8617 mL

5 mM

0.2372 mL

1.1862 mL

2.3723 mL

10 mM

0.1186 mL

0.5931 mL

1.1862 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhu P, et al. Hydroxylation and hydrolysis: two main metabolic ways of spiramycin I in anaerobic digestion. Bioresour Technol. 2014 Feb;153:95-100. [Content Brief]

[2]. Klich K, et al., Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm. J Med Chem. 2016 Sep 8;59(17):7963-73. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1862 mL	5.9308 mL	11.8617 mL	29.6542 mL
	5 mM	0.2372 mL	1.1862 mL	2.3723 mL	5.9308 mL
	10 mM	0.1186 mL	0.5931 mL	1.1862 mL	2.9654 mL
	15 mM	0.0791 mL	0.3954 mL	0.7908 mL	1.9769 mL
	20 mM	0.0593 mL	0.2965 mL	0.5931 mL	1.4827 mL
	25 mM	0.0474 mL	0.2372 mL	0.4745 mL	1.1862 mL
	30 mM	0.0395 mL	0.1977 mL	0.3954 mL	0.9885 mL
	40 mM	0.0297 mL	0.1483 mL	0.2965 mL	0.7414 mL
	50 mM	0.0237 mL	0.1186 mL	0.2372 mL	0.5931 mL
	60 mM	0.0198 mL	0.0988 mL	0.1977 mL	0.4942 mL
	80 mM	0.0148 mL	0.0741 mL	0.1483 mL	0.3707 mL
	100 mM	0.0119 mL	0.0593 mL	0.1186 mL	0.2965 mL

Keywords

Spiramycin I

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Spiramycin I

Anti-Infection Compound Library

Natural Product Library

Macrocyclic Compound Library

Antibacterial Compound Library

Antibiotics Library

Antiparasitic Compound library

Microbial Metabolite Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Spiramycin I

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Spiramycin I

Anti-Infection Compound Library

Natural Product Library

Macrocyclic Compound Library

Antibacterial Compound Library

Antibiotics Library

Antiparasitic Compound library

Microbial Metabolite Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Spiramycin I

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Spiramycin I Related Classifications

HY-N7141 Related Classifications